1
|
Bernardinello N, Crestani B, Spagnolo P, Ghanem M, Homps-Legrand M, Morer L, Goletto T, Frija-Masson J, Bancal C, Hurtado-Nedelec M, de Chaisemartin L, Debray MP, Neukirch C, Taillé C, Ba I, Kannengiesser C, Lainey E, Abels A, Vankann L, Beier F, Borie R. Is telomere length a predictor of long-term survival in patients with COVID-19 pneumonia? Respir Med Res 2023; 84:101048. [PMID: 37826871 DOI: 10.1016/j.resmer.2023.101048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 09/05/2023] [Accepted: 09/05/2023] [Indexed: 10/14/2023]
Affiliation(s)
- Nicol Bernardinello
- Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy; Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Bruno Crestani
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Paolo Spagnolo
- Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - Mada Ghanem
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France; Laboratoire d'excellence INFLAMEX, Universite de Paris, Inserm, U1152, Paris, France
| | - Méline Homps-Legrand
- Laboratoire d'excellence INFLAMEX, Universite de Paris, Inserm, U1152, Paris, France
| | - Lise Morer
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Tiphaine Goletto
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Justine Frija-Masson
- Service de Physiologie Explorations Fonctionnelles, APHP, et Université de Paris, Inserm Neurodiderot F-75018 France
| | - Catherine Bancal
- Service de Physiologie Explorations Fonctionnelles, APHP, et Université de Paris, Inserm Neurodiderot F-75018 France
| | | | - Luc de Chaisemartin
- Universite Paris-Sud, Université Paris-Saclay, APHP, Laboratoire d'immunologie, Hôpital Bichat, Paris, France, Inserm, Châtenay-Malabry, France
| | - Marie Pierre Debray
- Laboratoire d'excellence INFLAMEX, Universite de Paris, Inserm, U1152, Paris, France
| | - Catherine Neukirch
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Camille Taillé
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Ibrahima Ba
- Université de Paris, INSERM 1152, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de génétique, DHU APOLLO, Paris, France
| | - Caroline Kannengiesser
- Université de Paris, INSERM 1152, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de génétique, DHU APOLLO, Paris, France
| | - Elodie Lainey
- Hematology Laboratory, Robert Debré Hospital-Assistance Publique-Hôpitaux de Paris (APHP), INSERM UMR 1131-Hematology University Institute-Denis Diderot School of Medicine, Paris, France
| | - Anne Abels
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Lucia Vankann
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Fabian Beier
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Germany
| | - Raphaël Borie
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France.
| |
Collapse
|
2
|
Briard M, Godet C, Mouren D, Weisenburger G, Mal H, Messika J, Salpin M, Goletto T, Bunel V, Veyrier M. [Cushing's syndrome with inhaled corticosteroid: Drug interactions to avoid]. Rev Mal Respir 2023; 40:834-837. [PMID: 37743223 DOI: 10.1016/j.rmr.2023.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 07/31/2023] [Indexed: 09/26/2023]
Abstract
Cushing's syndrome is an iatrogenic event occurring during co-administration of inhaled corticosteroids and potent inhibitors of P450 cytochromes. We report the clinical case of a 29-year-old woman with a past history of asthma treated with inhaled fluticasone propionate (FP), chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis (ABPA) treated with itraconazole (ITZ), and Mycobacterium xenopi infection treated with moxifloxacin (MXF), ethambutol (EMB) and clarithromycin (CLR). Four months after initiation of antibiotic and antifungal medication, the patient contracted Cushing's syndrome. Its etiology consisted in interaction between FP, ITZ and CLR, which led to pronouncedly increased corticosteroid concentrations in circulating plasma cells. Following on the one hand cessation of FP and ITZ and on the other hand hydrocortisone supplementation, evolution was favorable. Several cases of iatrogenic Cushing's syndrome induced by co-administration of FP and potent CYP3A4 inhibitors have been reported in the literature. If possible, FP should be avoided in patients being treated with CYP3A4 inhibitors. Due to its differing physicochemical properties, beclometasone may be considered as the safest therapeutic alternative.
Collapse
Affiliation(s)
- M Briard
- AP-HP Nord-Université Paris-Cité, hôpital Bichat-Claude Bernard, service de pharmacie, 75018 Paris, France.
| | - C Godet
- AP-HP Nord-Université Paris-Cité, hôpital Bichat-Claude Bernard, service de pneumologie B et transplantation pulmonaire, Paris, France; Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université Paris-Cité, Paris, France
| | - D Mouren
- AP-HP Nord-Université Paris-Cité, hôpital Bichat-Claude Bernard, service de pneumologie B et transplantation pulmonaire, Paris, France
| | - G Weisenburger
- AP-HP Nord-Université Paris-Cité, hôpital Bichat-Claude Bernard, service de pneumologie B et transplantation pulmonaire, Paris, France; Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université Paris-Cité, Paris, France
| | - H Mal
- AP-HP Nord-Université Paris-Cité, hôpital Bichat-Claude Bernard, service de pneumologie B et transplantation pulmonaire, Paris, France; Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université Paris-Cité, Paris, France
| | - J Messika
- AP-HP Nord-Université Paris-Cité, hôpital Bichat-Claude Bernard, service de pneumologie B et transplantation pulmonaire, Paris, France; Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université Paris-Cité, Paris, France
| | - M Salpin
- AP-HP Nord-Université Paris-Cité, hôpital Bichat-Claude Bernard, service de pneumologie B et transplantation pulmonaire, Paris, France
| | - T Goletto
- AP-HP Nord-Université Paris-Cité, hôpital Bichat-Claude Bernard, service de pneumologie B et transplantation pulmonaire, Paris, France
| | - V Bunel
- AP-HP Nord-Université Paris-Cité, hôpital Bichat-Claude Bernard, service de pneumologie B et transplantation pulmonaire, Paris, France; Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université Paris-Cité, Paris, France
| | - M Veyrier
- AP-HP Nord-Université Paris-Cité, hôpital Bichat-Claude Bernard, service de pharmacie, 75018 Paris, France
| |
Collapse
|
3
|
Tanaka S, Tymowski CD, Tran-Dinh A, Meilhac O, Lortat-Jacob B, Zappella N, Jean-Baptiste S, Robert T, Goletto T, Godet C, Castier Y, Mal H, Mordant P, Atchade E, Messika J, Montravers P. Low HDL-Cholesterol Concentrations in Lung Transplant Candidates are Strongly Associated With One-Year Mortality After Lung Transplantation. Transpl Int 2023; 36:10841. [PMID: 36726695 PMCID: PMC9884674 DOI: 10.3389/ti.2023.10841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 01/03/2023] [Indexed: 01/26/2023]
Abstract
High-density lipoproteins (HDLs), whose main role is the reverse transport of cholesterol, also have pleiotropic anti-inflammatory, antioxidant, anti-apoptotic and anti-infectious properties. During sepsis, HDL cholesterol (HDL-C) concentration is low, HDL particle functionality is altered, and these modifications are correlated with poor outcomes. Based on the protective effects of HDL, we hypothesized that HDL-C levels could be associated with lung transplantation (LT) outcome. We thus looked for an association between basal HDL-C concentration and one-year mortality after LT. In this single-center prospective study including consecutive LTs from 2015 to 2020, 215 patients were included, essentially pulmonary fibrosis (47%) and chronic obstructive pulmonary disease (COPD) (38%) patients. Mortality rate at one-year was 23%. Basal HDL-C concentration stratified nonsurvivors to survivors at one-year (HDL-C = 1.26 [1.12-1.62] mmol/L vs. HDL-C = 1.55 [1.22-1.97] mmol/L, p = 0.006). Multivariate analysis confirmed that HDL-C concentration during the pretransplant assessment period was the only variable inversely associated with mortality. Moreover, mortality at one-year in patients with HDL-C concentrations ≤1.45 mmol/L was significantly higher (log-rank test, p = 0.00085). In conclusion, low basal HDL-C concentrations in candidates for LT are strongly associated with mortality after LT. To better understand this association, further studies in this field are essential and, in particular, a better characterization of HDL particles seems necessary.
Collapse
Affiliation(s)
- Sébastien Tanaka
- Department of Anesthesiology and Critical Care Medicine, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France,French Institute of Health and Medical Research (INSERM), U1188 Diabetes Atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Platform, Réunion Island University, Saint-Denis de La Réunion, France,*Correspondence: Sébastien Tanaka,
| | - Christian De Tymowski
- Department of Anesthesiology and Critical Care Medicine, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France,French Institute of Health and Medical Research (INSERM) U1149, Center for Research on Inflammation, Paris, France
| | - Alexy Tran-Dinh
- Department of Anesthesiology and Critical Care Medicine, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France,UFR Paris Nord, Université Paris Cité, Paris, France,Laboratory for Vascular Translational Science, French Institute of Health and Medical Research (INSERM) U1148, Paris, France
| | - Olivier Meilhac
- French Institute of Health and Medical Research (INSERM), U1188 Diabetes Atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Platform, Réunion Island University, Saint-Denis de La Réunion, France,Reunion Island University-Affiliated Hospital, Saint-Denis, France
| | - Brice Lortat-Jacob
- Department of Anesthesiology and Critical Care Medicine, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France
| | - Nathalie Zappella
- Department of Anesthesiology and Critical Care Medicine, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France
| | - Sylvain Jean-Baptiste
- Department of Anesthesiology and Critical Care Medicine, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France
| | - Tiphaine Robert
- Department of Biochemistry, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France
| | - Tiphaine Goletto
- Department of Pneumology and Lung Transplantation, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France
| | - Cendrine Godet
- Department of Pneumology and Lung Transplantation, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France,PHERE, Physiopathology and Epidemiology of Respiratory Diseases, French Institute of Health and Medical Research (INSERM) U1152, Paris, France
| | - Yves Castier
- UFR Paris Nord, Université Paris Cité, Paris, France,Laboratory for Vascular Translational Science, French Institute of Health and Medical Research (INSERM) U1148, Paris, France,Department of Vascular and Thoracic Surgery, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France
| | - Hervé Mal
- UFR Paris Nord, Université Paris Cité, Paris, France,Department of Pneumology and Lung Transplantation, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France,PHERE, Physiopathology and Epidemiology of Respiratory Diseases, French Institute of Health and Medical Research (INSERM) U1152, Paris, France
| | - Pierre Mordant
- UFR Paris Nord, Université Paris Cité, Paris, France,Laboratory for Vascular Translational Science, French Institute of Health and Medical Research (INSERM) U1148, Paris, France,Department of Vascular and Thoracic Surgery, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France
| | - Enora Atchade
- Department of Anesthesiology and Critical Care Medicine, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France
| | - Jonathan Messika
- UFR Paris Nord, Université Paris Cité, Paris, France,Department of Pneumology and Lung Transplantation, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France,PHERE, Physiopathology and Epidemiology of Respiratory Diseases, French Institute of Health and Medical Research (INSERM) U1152, Paris, France,Paris Transplant Group, Paris, France
| | - Philippe Montravers
- Department of Anesthesiology and Critical Care Medicine, Assistance Publique—Hôpitaux de Paris (AP-HP), Bichat-Claude Bernard Hospital, Paris, France,UFR Paris Nord, Université Paris Cité, Paris, France,PHERE, Physiopathology and Epidemiology of Respiratory Diseases, French Institute of Health and Medical Research (INSERM) U1152, Paris, France
| | | |
Collapse
|
4
|
Halitim P, Weisenburger G, Bunel-Gourdy V, Godet C, Salpin M, Mouren D, Thibaut de Menonville C, Goletto T, Medraoui C, Tran Dinh A, Mordant P, Messika J, Mal H. [Spontaneous pneumomediastinum]. Rev Mal Respir 2022; 39:228-240. [PMID: 35331625 DOI: 10.1016/j.rmr.2021.12.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 09/29/2021] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Pneumomediastinum, which can be spontaneous or secondary, is defined by the presence of free air in the mediastinum as shown on a chest X-ray and/or chest CT, with or without subcutaneous emphysema. Secondary pneumomediastinum develops in various contexts (thoracic traumatism, perforation of central airway or digestive tract, pneumothorax, barotraumatism complicating mechanical ventilation…). Spontaneous pneumomediastinum , which will be the focus of this review, develops without any of the above-mentioned conditions. STATE OF ART Spontaneous pneumomediastinum is a rare entity which usually occurs in young people either without medical history or with an history of asthma. A trigger event is detected in 40% to 60% of cases. Positive diagnosis is made on chest radiographt but thoracic CT is more sensitive. Distinction between spontaneous pneumomediastinum and secondary pneumomediastinum is in general easy but may sometimes be more difficult, particularly in case of oesophageal perforation. The evolution of spontaneous pneumomediastinum is most often benign but, rare complications may occur. Management is most often conservative. PERSPECTIVES There is no consensual management of spontaneous pneumediastinum because of the lack of randomized prospective studies. This may be explained by the rarity of the disease. The actual trend is to offer to the patients a conservative treatment, which could be ambulatory in some cases. CONCLUSIONS Spontaneous pneumomediastinum is a rare entity developing mainly in young subjects. The evolution is in general benign, justifying a conservative approach.
Collapse
Affiliation(s)
- P Halitim
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - G Weisenburger
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - V Bunel-Gourdy
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France; Service de chirurgie vasculaire, thoracique et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - C Godet
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - M Salpin
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - D Mouren
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - C Thibaut de Menonville
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - T Goletto
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - C Medraoui
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - A Tran Dinh
- Service d'anesthésie et réanimation chirurgicale, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - P Mordant
- Service de chirurgie vasculaire, thoracique et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France
| | - J Messika
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France; Inserm UMR1152, université Paris7 Denis Diderot, 75018 Paris, France
| | - H Mal
- Service de pneumologie B et transplantation pulmonaire, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France; Inserm UMR1152, université Paris7 Denis Diderot, 75018 Paris, France.
| |
Collapse
|
5
|
Goletto T, Decaux S, Bunel V, Weisenburger G, Messika J, Najem S, Medraoui C, Godet C, Debray MP, Lortat-Jacob B, Mordant P, Castier Y, Bouadma L, Borie R, Mal H. Acute worsening of native lung fibrosis after single lung transplantation for pulmonary fibrosis: two case reports. J Med Case Rep 2022; 16:2. [PMID: 34980231 PMCID: PMC8721472 DOI: 10.1186/s13256-021-03191-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Accepted: 11/15/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND In patients receiving single lung transplantation for idiopathic pulmonary fibrosis, worsening of fibrosis of the native lung is usually progressive over time, with no significant effects on gas exchange. CASE PRESENTATION Here, we describe the cases of two Caucasian male recipients of single lung transplants for idiopathic pulmonary fibrosis, 65 and 62 years of age, who exhibited acute worsening of lung fibrosis after an episode of serious viral infection (cytomegalovirus primo-infection in one case and COVID-19 in the other). In both cases, along with opacification of the native lung over several days, the patients presented acute respiratory failure that required the use of high-flow nasal oxygen therapy. Eventually, hypoxemic respiratory failure resolved, but with rapid progression of fibrosis of the native lung. CONCLUSION We conclude that acute worsening of fibrosis on the native lung secondary to a severe viral infection should be added to the list of potential complications developing on the native lung after single lung transplantation for idiopathic pulmonary fibrosis.
Collapse
Affiliation(s)
- Tiphaine Goletto
- Service de Pneumologie B, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018, Paris, France
- Inserm UMR1152, Université Paris7 Denis Diderot, 75018, Paris, France
| | - Sixtine Decaux
- Service de Pneumologie B, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018, Paris, France
- Inserm UMR1152, Université Paris7 Denis Diderot, 75018, Paris, France
| | - Vincent Bunel
- Service de Pneumologie B, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018, Paris, France
- Inserm UMR1152, Université Paris7 Denis Diderot, 75018, Paris, France
| | - Gaëlle Weisenburger
- Service de Pneumologie B, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018, Paris, France
- Inserm UMR1152, Université Paris7 Denis Diderot, 75018, Paris, France
| | - Jonathan Messika
- Service de Pneumologie B, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018, Paris, France
- Inserm UMR1152, Université Paris7 Denis Diderot, 75018, Paris, France
| | - Samer Najem
- Service de Pneumologie B, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018, Paris, France
- Inserm UMR1152, Université Paris7 Denis Diderot, 75018, Paris, France
| | - Chahine Medraoui
- Service de Pneumologie B, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018, Paris, France
- Inserm UMR1152, Université Paris7 Denis Diderot, 75018, Paris, France
| | - Cendrine Godet
- Service de Pneumologie B, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018, Paris, France
- Inserm UMR1152, Université Paris7 Denis Diderot, 75018, Paris, France
| | | | | | - Pierre Mordant
- Service de Chirurgie Vasculaire, Thoracique et Transplantation Pulmonaire, Hôpital Bichat, Paris, France
| | - Yves Castier
- Service de Chirurgie Vasculaire, Thoracique et Transplantation Pulmonaire, Hôpital Bichat, Paris, France
| | - Lila Bouadma
- Service de Réanimation Médicale et Infectieuse, Hôpital Bichat, Paris, France
| | - Raphael Borie
- Service de Pneumologie A, Hôpital Bichat, Paris, France
| | - Hervé Mal
- Service de Pneumologie B, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018, Paris, France.
- Inserm UMR1152, Université Paris7 Denis Diderot, 75018, Paris, France.
- Service de Pneumologie B et Transplantation Pulmonaire, Hôpital Bichat, 46 rue Henri Huchard, 75018, Paris, France.
| |
Collapse
|
6
|
Ghanem M, Homps-Legrand M, Garnier M, Morer L, Goletto T, Frija-Masson J, Wicky PH, Jaquet P, Bancal C, Hurtado-Nedelec M, de Chaisemartin L, Jaillet M, Mailleux A, Quesnel C, Poté N, Debray MP, de Montmollin E, Neukirch C, Borie R, Taillé C, Crestani B. Blood fibrocytes are associated with severity and prognosis in COVID-19 pneumonia. Am J Physiol Lung Cell Mol Physiol 2021; 321:L847-L858. [PMID: 34496650 PMCID: PMC8562948 DOI: 10.1152/ajplung.00105.2021] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Increased blood fibrocytes are associated with a poor prognosis in fibrotic lung diseases. We aimed to determine whether the percentage of circulating fibrocytes could be predictive of severity and prognosis during coronavirus disease 2019 (COVID-19) pneumonia. Blood fibrocytes were quantified by flow cytometry as CD45+/CD15-/CD34+/collagen-1+ cells in patients hospitalized for COVID-19 pneumonia. In a subgroup of patients admitted in an intensive care unit (ICU), fibrocytes were quantified in blood and bronchoalveolar lavage (BAL). Serum amyloid P (SAP), transforming growth factor-β1 (TGF-β1), CXCL12, CCL2, and FGF2 concentrations were measured. We included 57 patients in the hospitalized group (median age = 59 yr [23-87]) and 16 individuals as healthy controls. The median percentage of circulating fibrocytes was higher in the patients compared with the controls (3.6% [0.2-9.2] vs. 2.1% [0.9-5.1], P = 0.04). Blood fibrocyte count was lower in the six patients who died compared with the survivors (1.6% [0.2-4.4] vs. 3.7% [0.6-9.2], P = 0.02). Initial fibrocyte count was higher in patients showing a complete lung computed tomography (CT) resolution at 3 mo. Circulating fibrocyte count was decreased in the ICU group (0.8% [0.1-2.0]), whereas BAL fibrocyte count was 6.7% (2.2-15.4). Serum SAP and TGF-β1 concentrations were increased in hospitalized patients. SAP was also increased in ICU patients. CXCL12 and CCL2 were increased in ICU patients and negatively correlated with circulating fibrocyte count. We conclude that circulating fibrocytes were increased in patients hospitalized for COVID-19 pneumonia, and a lower fibrocyte count was associated with an increased risk of death and a slower resolution of lung CT opacities.
Collapse
Affiliation(s)
- Mada Ghanem
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | - Méline Homps-Legrand
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France
| | - Marc Garnier
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,Sorbonne Université, APHP, DMU DREAM, Service d'Anesthésie-Réanimation et Médecine Périopératoire, Hôpital Tenon, Paris, France
| | - Lise Morer
- APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | - Tiphaine Goletto
- APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | | | - Paul-Henri Wicky
- APHP, Service de Réanimation Médicale et Infectieuse, Hôpital Bichat, Paris, France
| | - Pierre Jaquet
- APHP, Service de Réanimation Médicale et Infectieuse, Hôpital Bichat, Paris, France
| | - Catherine Bancal
- APHP, Laboratoire d'Explorations Fonctionnelles, Hôpital Bichat, Paris, France
| | | | - Luc de Chaisemartin
- Université Paris-Sud, Université Paris-Saclay, APHP, Laboratoire d'immunologie, Hôpital Bichat, Paris, France, Inserm, Châtenay-Malabry, France
| | - Madeleine Jaillet
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France
| | - Arnaud Mailleux
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France
| | - Christophe Quesnel
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,Sorbonne Université, APHP, DMU DREAM, Service d'Anesthésie-Réanimation et Médecine Périopératoire, Hôpital Tenon, Paris, France
| | - Nicolas Poté
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service d'Anatomie et Cytologie pathologique, Hôpital Bichat, Paris, France
| | - Marie-Pierre Debray
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Radiologie, Hôpital Bichat, Paris, France
| | | | - Catherine Neukirch
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | - Raphael Borie
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | - Camille Taillé
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | - Bruno Crestani
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | | |
Collapse
|
7
|
Savary A, Hammouda M, Genet L, Godet C, Bunel V, Weisenburger G, Goletto T, Medraoui C, Jebrak G, Marceau A, Tran-Dinh A, Mordant P, Castier Y, Montravers P, Mal H, Messika J. Coping strategies, anxiety and depression related to the COVID-19 pandemic in lung transplant candidates and recipients. Results from a monocenter series. Respir Med Res 2021; 80:100847. [PMID: 34371237 PMCID: PMC8260501 DOI: 10.1016/j.resmer.2021.100847] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 05/17/2021] [Accepted: 06/21/2021] [Indexed: 11/15/2022]
Abstract
BACKGROUND The COVID-19 pandemic has been associated with an increase in anxiety and depression symptoms in people. We investigated the impact of the pandemic on coping strategies and anxiety and depression in lung transplantation (LT) recipients and patients with end-stage chronic lung disease awaiting LT. METHODS We retrospectively investigated coping strategies by using the Coping Inventory for Stressful Situations questionnaire and anxiety and depression symptoms by the Hospital Anxiety and Depression scale in 115 LT candidates and recipients. RESULTS Overall, 63 participants (20 women; median age 59 years [interquartile range 52•65]) answered one or both questionnaires (49 LT recipients and 14 LT candidates). The preferred coping strategy was task-focused for 51 (86.4%) participants, with no difference between LT recipients and candidates nor according to the main anamnestic and clinical data. Eleven patients had suspected or proven depression symptoms, and 18 had suspected or proven anxiety symptoms. Coping strategies related to COVID-19 did not differ by presence of anxiety or depression symptoms. CONCLUSION In the current pandemic, healthcare professionals should consider these results to provide relevant psychological help to these fragile populations and promote a systematic and wide multidisciplinary assessment of LT recipients and candidates.
Collapse
Affiliation(s)
- Alice Savary
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France
| | - Malika Hammouda
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France
| | - Lucie Genet
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France
| | - Cendrine Godet
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France; Universitèc) de Paris, PHERE UMRS 1152, LVTS UMRS 1148, F-75018 Paris, France
| | - Vincent Bunel
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France; Universitèc) de Paris, PHERE UMRS 1152, LVTS UMRS 1148, F-75018 Paris, France
| | - Gaelle Weisenburger
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France; Universitèc) de Paris, PHERE UMRS 1152, LVTS UMRS 1148, F-75018 Paris, France
| | - Tiphaine Goletto
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France
| | - Chahine Medraoui
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France
| | - Gilles Jebrak
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France
| | - Armelle Marceau
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France
| | - Alexy Tran-Dinh
- Universitèc) de Paris, PHERE UMRS 1152, LVTS UMRS 1148, F-75018 Paris, France; APHP, Hôpital Bichat, Dèc)partement d'Anesthèc)sie et Rèc)animation, F-75018 Paris, France
| | - Pierre Mordant
- Universitèc) de Paris, PHERE UMRS 1152, LVTS UMRS 1148, F-75018 Paris, France; APHP, Hôpital Bichat, Chirurgie Vasculaire, Thoracique et Transplantation, F-75018 Paris, France
| | - Yves Castier
- Universitèc) de Paris, PHERE UMRS 1152, LVTS UMRS 1148, F-75018 Paris, France; APHP, Hôpital Bichat, Chirurgie Vasculaire, Thoracique et Transplantation, F-75018 Paris, France
| | - Philippe Montravers
- Universitèc) de Paris, PHERE UMRS 1152, LVTS UMRS 1148, F-75018 Paris, France; APHP, Hôpital Bichat, Dèc)partement d'Anesthèc)sie et Rèc)animation, F-75018 Paris, France
| | - Herve Mal
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France; Universitèc) de Paris, PHERE UMRS 1152, LVTS UMRS 1148, F-75018 Paris, France
| | - Jonathan Messika
- APHP, Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, F-75018 Paris, France; Universitèc) de Paris, PHERE UMRS 1152, LVTS UMRS 1148, F-75018 Paris, France; Paris Transplant Group, Paris, France.
| | | |
Collapse
|
8
|
Borie R, Savale L, Dossier A, Ghosn J, Taillé C, Visseaux B, Jebreen K, Diallo A, Tesmoingt C, Morer L, Goletto T, Faucher N, Hajouji L, Neukirch C, Phillips M, Stelianides S, Bouadma L, Brosseau S, Ottaviani S, Pluvy J, Le Pluart D, Debray MP, Raynaud-Simon A, Descamps D, Khalil A, Timsit JF, Lescure FX, Descamps V, Papo T, Humbert M, Crestani B, Dieude P, Vicaut E, Zalcman G. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. PLoS One 2020; 15:e0243961. [PMID: 33326457 PMCID: PMC7743937 DOI: 10.1371/journal.pone.0243961] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 12/02/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND The optimal treatment for patients with severe coronavirus-19 disease (COVID-19) and hyper-inflammation remains debated. MATERIAL AND METHODS A cohort study was designed to evaluate whether a therapeutic algorithm using steroids with or without interleukin-1 antagonist (anakinra) could prevent death/invasive ventilation. Patients with a ≥5-day evolution since symptoms onset, with hyper-inflammation (CRP≥50mg/L), requiring 3-5 L/min oxygen, received methylprednisolone alone. Patients needing ≥6 L/min received methylprednisolone + subcutaneous anakinra daily either frontline or in case clinical deterioration upon corticosteroids alone. Death rate and death or intensive care unit (ICU) invasive ventilation rate at Day 15, with Odds Ratio (OR) and 95% CIs, were determined according to logistic regression and propensity scores. A Bayesian analysis estimated the treatment effects. RESULTS Of 108 consecutive patients, 70 patients received glucocorticoids alone. The control group comprised 63 patients receiving standard of care. In the corticosteroid±stanakinra group (n = 108), death rate was 20.4%, versus 30.2% in the controls, indicating a 30% relative decrease in death risk and a number of 10 patients to treat to avoid a death (p = 0.15). Using propensity scores a per-protocol analysis showed an OR for COVID-19-related death of 0.9 (95%CI [0.80-1.01], p = 0.067). On Bayesian analysis, the posterior probability of any mortality benefit with corticosteroids+/-anakinra was 87.5%, with a 7.8% probability of treatment-related harm. Pre-existing diabetes exacerbation occurred in 29 of 108 patients (26.9%). CONCLUSION In COVID-19 non-ICU inpatients at the cytokine release phase, corticosteroids with or without anakinra were associated with a 30% decrease of death risk on Day 15.
Collapse
Affiliation(s)
- Raphael Borie
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Laurent Savale
- Pulmonology Department, Kremlin-Bicêtre University Hospital, AP-HP, Paris-Saclay University, Kremlin-Bicêtre, France
| | - Antoine Dossier
- Internal Medicine Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Jade Ghosn
- Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Camille Taillé
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Benoit Visseaux
- Virology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Kamel Jebreen
- Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France
| | - Abourahmane Diallo
- Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France
| | - Chloe Tesmoingt
- Pharmacy Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Lise Morer
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Tiphaine Goletto
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Nathalie Faucher
- Geriatrics Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Linda Hajouji
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Catherine Neukirch
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Mathilde Phillips
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Sandrine Stelianides
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Lila Bouadma
- Medical and infectious Diseases ICU, Intensive Care Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Solenn Brosseau
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Sébastien Ottaviani
- Rheumatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Johan Pluvy
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Diane Le Pluart
- Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Marie-Pierre Debray
- Radiology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Agathe Raynaud-Simon
- Pharmacy Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Diane Descamps
- Virology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Antoine Khalil
- Radiology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Jean Francois Timsit
- Medical and infectious Diseases ICU, Intensive Care Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Francois-Xavier Lescure
- Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Vincent Descamps
- Dermatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Thomas Papo
- Internal Medicine Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Marc Humbert
- Pulmonology Department, Kremlin-Bicêtre University Hospital, AP-HP, Paris-Saclay University, Kremlin-Bicêtre, France
| | - Bruno Crestani
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Philippe Dieude
- Rheumatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Eric Vicaut
- Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France
| | - Gérard Zalcman
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | | |
Collapse
|
9
|
Bondeelle L, Chevret S, Hurabielle C, Samy L, Goletto T, Costantini A, Sicre de Fontbrune F, Michonneau D, Socié G, Tazi A, Bouaziz JD, Bergeron A. Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2020; 26:2115-2120. [PMID: 32738501 DOI: 10.1016/j.bbmt.2020.07.033] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 06/23/2020] [Accepted: 07/26/2020] [Indexed: 12/11/2022]
Abstract
Ruxolitinib, a selective Janus kinase (JAK)1/2 inhibitor, has recently been proposed for steroid-refractory chronic graft-versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in severe skin cGVHD. Lung function impairment is common in severe skin cGVHD through concomitant bronchiolitis obliterans syndrome (BOS) or restrictive lung disease (RLD) from skin sclerosis. To date, no treatment has shown a benefit on lung function in this context. We retrospectively assessed the effect of ruxolitinib on lung function in a cohort of 70 patients diagnosed with sclerotic-type skin cGVHD between March 2015 and April 2018. Among these patients, 36 received ruxolitinib. To handle confounding by indication bias, exposure groups were matched on the propensity score to receive ruxolitinib, incorporating age, myeloablative conditioning, total body irradiation, BOS, forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and tobacco use at the time of cohort entry, as well as the time from transplantation. The 1:1 matching used a greedy-matching algorithm with replacement, with a caliper of 0.10. FVC and FEV1 trajectories during follow-up were compared in the matched samples, using linear mixed-effects models. The median duration of follow-up of the 46 matched patients was 58 months (interquartile range, 32 to 84 months). Ten patients had an RLD (6 exposed, 4 unexposed), and 13 patients were diagnosed with BOS (8 exposed, 5 unexposed). FEV1 decreased significantly over time independent of exposure to ruxolitinib (P < .0001). The FEV1 trajectory was similar in the exposed patients and the unexposed patients (P = .11). In conclusion, ruxolitinib administration did not demonstrate any improvement in the course of respiratory function in allogeneic HSCT recipients with sclerotic-type skin cGVHD.
Collapse
Affiliation(s)
- Louise Bondeelle
- Pneumology Department, Service de Pneumologie, Université de Paris, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Sylvie Chevret
- ECSTRRA Team, Université de Paris, INSERM, UMR 1153 CRESS, Paris, France; Biostatistics and Medical data Department, Service de Biostatistique et Information Médicale, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Charlotte Hurabielle
- Dermatology Department, Service de Dermatologie, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Laila Samy
- Pneumology Department, Service de Pneumologie, Université de Paris, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Tiphaine Goletto
- Pneumology Department, Service de Pneumologie, Université de Paris, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Adrien Costantini
- Pneumology Department, Service de Pneumologie, Université de Paris, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Flore Sicre de Fontbrune
- Hematology-Bone marrow transplant Unit, Hématologie-Greffe, Hôpital St Louis, APHP, Paris, France
| | - David Michonneau
- Hematology-Bone marrow transplant Unit, Hématologie-Greffe, Hôpital St Louis, APHP, Paris, France
| | - Gérard Socié
- Hematology-Bone marrow transplant Unit, Hématologie-Greffe, Hôpital St Louis, APHP, Paris, France
| | - Abdellatif Tazi
- Pneumology Department, Service de Pneumologie, Université de Paris, Hôpital Saint-Louis, AP-HP, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Jean-David Bouaziz
- Dermatology Department, Service de Dermatologie, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Anne Bergeron
- Pneumology Department, Service de Pneumologie, Université de Paris, Hôpital Saint-Louis, AP-HP, Paris, France; ECSTRRA Team, Université de Paris, INSERM, UMR 1153 CRESS, Paris, France.
| |
Collapse
|
10
|
Maillet T, Goletto T, Beltramo G, Dupuy H, Jouneau S, Borie R, Crestani B, Cottin V, Blockmans D, Lazaro E, Naccache JM, Pugnet G, Nunes H, de Menthon M, Devilliers H, Bonniaud P, Puéchal X, Mouthon L, Bonnotte B, Guillevin L, Terrier B, Samson M. Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. J Autoimmun 2019; 106:102338. [PMID: 31570253 DOI: 10.1016/j.jaut.2019.102338] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 09/20/2019] [Accepted: 09/23/2019] [Indexed: 02/02/2023]
Abstract
BACKGROUND Progressive fibrosing interstitial lung disease (ILD) is rarely associated with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). This study focused on the outcomes of ILD patients with associated AAV (AAV-ILD). METHODS AAV-ILD (cases: microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) with ILD) were compared to AAV patients without ILD (controls). ILD was defined as a usual interstitial pneumonia (UIP) or non-specific interstitial pneumonia (NSIP) pattern. Two controls were matched to each case for age (>or ≤65 years), ANCA status (PR3-or MPO-positive) and creatininemia (≥or <150 μmol/L). RESULTS Sixty-two cases (89% MPO-ANCA+) were included. Median age at AAV diagnosis was 66 years. ILD (63% UIP), was diagnosed before (52%) or simultaneously (39%) with AAV. Cases versus 124 controls less frequently had systemic vasculitis symptoms. One-, 3- and 5-year overall survival rates, respectively, were: 96.7%, 80% and 66% for cases versus 93.5%, 89.6% and 83.8% for controls (p = 0.008). Multivariate analyses retained age >65 years (hazard ratio (HR) 4.54; p < 0.001), alveolar haemorrhage (HR 2.25; p = 0.019) and UIP (HR 2.73; p = 0.002), but not immunosuppressant use, as factors independently associated with shorter survival. CONCLUSION For AAV-ILD patients, only UIP was associated with poorer prognosis. Immunosuppressants did not improve the AAV-ILD prognosis. But in analogy to idiopathic pulmonary fibrosis, anti-fibrosing agents might be useful and should be assessed in AAV-ILD patients with a UIP pattern.
Collapse
Affiliation(s)
- Thibault Maillet
- Department of Internal Medicine and Clinical Immunology, CHU Dijon Bourgogne, Dijon, France
| | - Tiphaine Goletto
- Department of Pulmonology, Hôpital Saint-Louis, APHP, Paris, France
| | - Guillaume Beltramo
- Respiratory and ICU Department, Referral Center for Adults Rare Pulmonary Diseases, Inserm 1231, CHU Dijon-Bourgogne, Dijon, France
| | - Henry Dupuy
- Department of Internal Medicine and Infectious Diseases, Hôpital Haut-Lévêque, Bordeaux, France
| | - Stéphane Jouneau
- Department of Pulmonology, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail), UMR S, 1085, Rennes, France
| | - Raphael Borie
- Department of Pulmonology, Hôpital Bichat, APHP, Paris, France
| | - Bruno Crestani
- Department of Pulmonology, Hôpital Bichat, APHP, Paris, France
| | - Vincent Cottin
- Department of Pulmonology, Hôpital Louis-Pradel, Bron, France
| | - Daniel Blockmans
- Department of Internal Medicine, UZ Leuven Hospital, Leuven, Belgium
| | - Estibaliz Lazaro
- Department of Internal Medicine and Infectious Diseases, Hôpital Haut-Lévêque, Bordeaux, France
| | - Jean-Marc Naccache
- Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Tenon, Service de Pneumologie, Site Constitutif Du Centre de Référence des Maladies Pulmonaires Rares OrphaLung, Paris, France
| | - Grégory Pugnet
- Department of Internal Medicine, CHU de Toulouse, Toulouse, France
| | - Hilario Nunes
- Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France
| | - Mathilde de Menthon
- Department of Internal Medicine, Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France
| | - Hervé Devilliers
- Department of Internal Medicine and Systemic Diseases, CHU Dijon-Bourgogne, Dijon, France
| | - Philippe Bonniaud
- Respiratory and ICU Department, Referral Center for Adults Rare Pulmonary Diseases, Inserm 1231, CHU Dijon-Bourgogne, Dijon, France
| | - Xavier Puéchal
- Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, APHP, Inserm U1016, Université Paris Descartes, Paris, France
| | - Luc Mouthon
- Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, APHP, Inserm U1016, Université Paris Descartes, Paris, France
| | - Bernard Bonnotte
- Department of Internal Medicine and Clinical Immunology, CHU Dijon Bourgogne, Dijon, France
| | - Loïc Guillevin
- Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, APHP, Inserm U1016, Université Paris Descartes, Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, APHP, Inserm U1016, Université Paris Descartes, Paris, France
| | - Maxime Samson
- Department of Internal Medicine and Clinical Immunology, CHU Dijon Bourgogne, Dijon, France
| | | |
Collapse
|
11
|
Maillet T, Goletto T, Dupuy H, Jouneau S, Cottin V, Devilliers H, Lazaro E, Bonniaud P, Puéchal X, Guillevin L, Terrier B, Samson M. Fibrose pulmonaire au cours des vascularites associées aux ANCA : un facteur pronostique. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.03.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
12
|
Goletto T, Zemoura L, Rivaud E, Catherinot E, Bron-Chastre C, Tcherakian C, Couderc L. Benfluorex et maladies pleurales. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|